Johnson & Johnson (JNJ) reported its Q3 2025 financial results, delivering earnings that aligned with analyst expectations. The company posted earnings per share (EPS) of $2.80, surpassing the consensus estimate of $2.78 by $0.02. Revenue also came in at $24.0 billion, matching analyst forecasts.
This update provides insight into Johnson & Johnson's operational performance and financial health. Meeting these expectations suggests that the company's performance is in line with market forecasts.
The company will host an earnings conference call at 8:00 AM ET to discuss these results and provide further commentary on business performance. Investors are encouraged to review the full earnings release and listen to management's insights for a complete context on the quarter's performance and future outlook.
Headquartered in New Brunswick, New Jersey, Johnson & Johnson operates in the pharmaceuticals industry, focusing on the research, development, manufacture, and sale of healthcare products. The company employs approximately 138,100 full-time employees and is structured into two main segments: Innovative Medicine and MedTech.
Looking ahead, analysts estimate that the company will report an EPS of $2.9234 and revenue of $25.0 billion for the upcoming quarter on July 13, 2026.